Oncology
Multiple solid and liquid tumors Wholly owned
Metastasis (High-CIN) Partnering with
These droplets form dynamically throughout the cell via a process called phase separation. Their behavior is governed by weak multivalent interactions between proteins and nucleic acids.
Condensates compartmentalize and concentrate molecules, enabling key biochemical processes.
When something goes awry with a condensate’s composition or behavior, we call it condensatopathy.
Condensatopathies can sequester proteins needed elsewhere in the cell, exclude proteins needed for critical processes, or have altered physical properties that lead to toxic gain of function.
Condensate modulators (c-mods) are uniquely designed to hit condensate targets and reverse condensatopathies by:
Genetic and environmental factors
TDP43 sequestration
Alters condensate composition to release TDP43
Stathmin-2 mis-splicing, improper RNA trafficking, TDP43 proteinopathy
ALS
Mutations in RBM20
RBM20 sequestration
Dissolve condensate to release RBM20
Mis-splicing of Titin, RyR2, and CamkIIδ
Aberrant Ca2+ handling
Dilated cardiomyopathy
Our comprehensive technology suite allows us to identify novel drugs across a wide spectrum of diseases.
Engine for genetically linked condensatopathy discovery
Machine-learning-based image analysis tools for visualizing condensates
Proprietary knowledge base of biomolecules in condensates
Compendium of all condensates in different cell types
Collection of engineered cell lines with trackable condensates
Suite of reconstituted physiologically relevant cell-free condensates
Condensate-directed medicinal chemistry
Methods for monitoring drug partitioning into condensates
Integrated machine learning platform automates, speeds, and enhances c-mod discovery
Discovering and developing c-mods to address true unmet need
Multiple solid and liquid tumors Wholly owned
Metastasis (High-CIN) Partnering with
Rare diseases and repeat expansion disorders Wholly owned
DM-1 Partnering with
Multiple Partnering with
Multiple viral targets Wholly owned
HIV Partnering with
Building on condensate science, from concept to company
1903Science
Peering through an early microscope, Santiago Ramón y Cajal saw membraneless structures now known to be condensates.
June, 2009Science
Tony Hyman and colleagues describe research in Science that begins to unravel the mysteries of biomolecular condensates.
February, 2018Science
Phil Sharp identifies condensate biology as a once-in-a-generation opportunity to make transformative new medicines.
August, 2018Company
Tony Hyman, Rick Young, and Amir Nashat decide to found company, with Phil Sharp as chair of the SAB.
September, 2018Company
Founding team sketches out Dewpoint’s strategy. Suzanne Eaton, a brilliant scientist and partner to Tony Hyman, gives the company its name.
October, 2018Company
The emerging science of biomolecular condensates could help answer some of biology’s biggest questions.
Learn more about Dewpoint's history
Our founders and advisors explain how condensates drive cell function and solve biological mysteries.
Biomolecular condensates can fuse over time.
P granules segregate asymmetrically during embryogenesis.
Protein mutants cause aberrant phase transition.
Leading thinkers in cell biology, biophysics, drug discovery, and medicinal chemistry come together at Dewpoint.
We are looking for passionate — and compassionate — scientists across a diverse set of scientific disciplines, including cell biology, high content cell imaging, biophysics, and proteomics.
It's this open minded community we have here and you're respected even if you're not a PhD. You can still contribute no matter what level you're at.
I feel supported and welcomed by everyone at all levels, and everyone is always willing to answer a question.
I have a voice here and I'm respected here.
News, events, resources, and insights by and for the condensate community.
Visit siteCurated by
Jan 30, 2023
Jan 30, 2023
Jan 30, 2023
Jan 30, 2023
Jan 30, 2023
Jan 29, 2023
Jan 29, 2023
Jan 29, 2023
Jan 28, 2023
Jan 28, 2023